Table 2.
AKI outcomes in the SGLT2 inhibitor user and nonuser groups in the Mount Sinai and Geisinger propensity-matched cohorts
| Mount Sinai cohort |
Geisinger cohort |
|||||
|---|---|---|---|---|---|---|
| User (n = 372) | Nonuser (n = 372) | P1 | User (n = 1,207) | Nonuser (n = 1,207) | P2 | |
| AKIKDIGO–inpatient | 14 (3.8) | 36 (9.7) | 0.002 | 26 (2.2) | 55 (4.6) | 0.001 |
| AKIICD | 22 (5.9) | 40 (10.8) | 0.02 | 15 (1.2) | 36 (3.0) | 0.003 |
| Peak creatinine in AKIKDIGO events | 1.6 (1.4–1.8) | 1.9 (1.6–2.4) | 0.02 | 1.7 (1.4–2.6) | 1.6 (1.3–2.4) | 0.91 |
| Change in serum creatinine during AKIKDIGO events | 0.5 (0.4–0.7) | 0.9 (0.8–1.3) | 0.004 | 0.6 (0.5–1.0) | 0.6 (0.4–1.2) | 0.80 |
| Need for acute dialysis | 1 (0.3) | 1 (0.3) | 1.00 | 0 (0.0) | 1 (0.1) | 0.317 |
P1 and P2 are P values for primary and secondary analyses, respectively.